Restless legs syndrome (RLS) is a chronic neurological disorder characterized by an urge to move the legs at night when at rest. RLS can lead to a sleep deprivation, increased falling risk, daytime sleepiness, depression and decreased quality of life. Dopamine agonists, alpha-2-delta ligands and opiates are key medications for RLS. The natural course of RLS is very heterogeneous with a risk of increasing the severity of symptoms over the years despite the use of drugs and recommended dosages. Many comorbidities can make RLS worse. Augmentation syndrome is the main complication of dopamine agonists. However, only a few studies have addressed the clinical, biological and pharmacological factors associated with the evolution of the severity of RLS. The objective of this study is to assess the evolution of RLS symptoms severity as function of RLS phenotype, comorbidities and RLS medication, in large cohort of members of the French RLS association and other European RLS association.
In this study, the investigators want to study the clinical course of RLS in a population of RLS patients who are members of the RLS patient association, taking into account clinical and biological factors as well as the treatments taken for RLS.
Study Type
OBSERVATIONAL
Enrollment
2,000
Uhmontpellier
Montpellier, France
RECRUITINGInternational restless legs syndrome study group rating scale (IRLS)
International restless legs syndrome study group rating scale (IRLS). ranging from 0 to 40, with higher scores indicating worse restless legs symptoms
Time frame: Four minutes
Restless Legs Syndrome-6 Scale (RLS-6)
Restless Legs Syndrome-6 Scale (RLS-6)symptoms after a surgical procedure under general or locoregional anesthesia. ranging from 0 to 60, with higher scores indicating worse restless legs symptoms
Time frame: two minutes
Augmentation Severity Rating Scale (ASRS)
Augmentation Severity Rating Scale (ASRS). ranging from 0 to 24, with higher scores indicating worse augmentation symptoms
Time frame: two minutes
Epworth severity scale (ESS)
Epworth severity scale (ESS). ranging from 0 to 24, with higher scores indicating worse sleepiness
Time frame: two minutes
Insomnia Severity Index (ISI)
Insomnia Severity Index (ISI). ranging from 0 to 28, with higher scores indicating worse insomnia
Time frame: two minutes
Beck's Depression Inventory - II (BDI-II)
Beck's Depression Inventory - II (BDI-II). ranging from 0 to 63, with higher scores indicating worse depressive symptoms
Time frame: Six minute
European Quality of life - 5 dimensions (EQ-5D)
European Quality of life - 5 dimensions (EQ-5D). ranging from 0 to 100. Higher scores indicate better health condition
Time frame: One minute
Homemade questionnaire assessing the falling risk
Homemade questionnaire assessing the falling risk. ranging from 0 to 6, with higher scores indicating worse falling risk
Time frame: Five minutes
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.